Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
How do you determine when to treat versus monitor subclinical thyroid disease early in pregnancy in patients with a negative TPOAb?
Related Questions
Does the degree of TSH suppression significantly impact the risk of differentiated thyroid carcinoma recurrence?
Are there specific populations with hypothyroidism for whom you would consider adding liothyronine to levothyroxine therapy, given observational data linking levothyroxine therapy alone to higher risks of dementia and mortality?
In middle-aged adults with TSH 5–10 mIU/L and no symptoms, would you start levothyroxine or monitor, and does your threshold change with cardiovascular risk factors?
Do you recommend prescribing methimazole to prevent iodinated contrast media-induced exacerbation of thyrotoxicosis in patients with pre-existing hyperthyroidism?
What empiric dose change, if any, do you make for patients already taking liquid or softgel levothyroxine preconception upon confirmation of a positive pregnancy test?
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
Under what circumstances do you consider deprescribing levothyroxine in patients with mild subclinical hypothyroidism?
What TSH cut off do you use to determine the need for levothyroxine supplementation in a pregnant patient with positive TPO antibodies?
How do you counsel patients on the risk of hypothyroidism after radioactive ablation for hot nodules?
Would you consider extending Tepezza treatment for thyroid eye disease management in patients with incomplete response?
